REMARKS

Applicants respectfully request entry of the amendments and remarks set forth herein prior to examination of the above-identified application on the merits pursuant to 37 C.F.R. § 1.115(a).

A Sequence Listing has not previously been filed in connection with this application. Support for the Sequence Listing enclosed herewith may be found in the Specification originally filed at, for example, Figure 1.

I hereby state that the content of the paper and computer readable copies of the Substitute Sequence Listing submitted in accordance with 37 C.F.R. §1.821(c) and (e), are the same. I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(g), herein does not include new matter.

Minor amendments have been made to the specification. These amendments have been made for the convenience of the reader in correlating the nucleotide numbering of the Sequence Listing with the nucleotide numbering of Figure 1. Applicants assert, therefore, that the instant amendment is fully supported by the application as filed and does not constitute new matter.

6

While Applicants do not believe that any fee is due with this submission, the Commissioner is hereby authorized to charge any fees due with this submission not otherwise enclosed to Deposit Account No. 02-0384

Respectfully submitted,

BAKER BOTTS L.L.P. Attorneys for Applicants

Michelle M. LeCointe Reg. No. 46,861

Date:

Correspondence Address:

Baker Botts L.L.P.

Customer No. **05073**

(512) 322-2580

(512) 322-8380 (FAX)